AR and prostate cancer: Activity of the PTEN/PI3K pathway has also been associated with AR expression in prostate cancer,20,36 and mouse models suggest that a functional AR may increase PTEN inactivation-induced uterine cancer.37 These data suggest that PTEN inactivation is positively selected by functional androgen activity in these tumour types.